Activities Discovered for Some Inactive Drug Ingredients

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

ruth williams
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ABOVE: © ISTOCK.COM, APOMARES

A series of tests including computational predictions, biological assays, and live-animal studies has revealed that while the majority of inactive drug ingredients are indeed inert, many can interact with biological targets with the potential to cause physiologically relevant effects. The findings are published today (July 23) in Science.

“It seems to me to be quite a tour de force,” says epidemiologist Mady Hornig of Columbia University who was not involved in the study. “We’ve been quite data-starved in this area in general,” she continues, “and this represents an important leap forward in terms of a strategy for identifying candidate [excipients] of concern.” She adds, however, that “it is so important to emphasize . . . these are candidates for concern, not definitive agents of concern.”

The success of a drug often depends not simply on the active ingredients it contains, but on how it is formulated, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo